

O P E  
JAN 07 2004  
PATENT & TRADEMARK OFFICE  
DECLARATION  
FOR PATENT APPLICATION

As a below named inventor(s), I/We hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s).  
 I/We verify believe I am/we are the original, first and sole/joint Inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

## INDOLE DERIVATIVES OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IKB KINASE

and the specification of which (check one)  is attached hereto (Aventis Docket No. DEAV2002/0063 US NP)  
 was filed on August 18, 2003 as U.S. Application Number 10/642,970  
 and was amended on (if applicable)  
 was described and claimed in PCT Int'l Application Number filed on  
 and as amended under PCT Article 19 on (if any).

I/We hereby state that I/We have reviewed and understand the contents of the above identified specification, including the claims as amended by any amendment referred to above. I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 C.F.R. 1.56.

I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Foreign Priority:	10237722.7	Germany	17/August/2002
	Number	Country	Day/Month/Year Filed

Prior Foreign Appn(s):	Number	Country	Day/Month/Year Filed

I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional application(s) listed below:

60/434,749	December 19, 2002
Number	Filing Date

I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States application(s) or international application designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Ave	Application Serial No.	Filing Date	Status (Patented, Pending)
Patte			
Rou			
P.O.			
Mail			
Brid			
Telep			
Telef			
Avent			

Docket No.: DEAV2002/0063 US NP  
Page 1 of 2

Page 2 of 2



JAN. 7, 2004 3:04PM

AVENTIS US PAT DEPT

NO. 5773 P. 6

Aventis Docket No. DEAV2002/0063 US NP

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: **RITZELER, et al.**

Examiner:

Serial No.: **10/642,970**

Group Art Unit.:

Filed: **August 18, 2003**

Title: **INDOLE DERIVATIVES OR  
BENZIMIDAZOLE DERIVATIVES FOR  
MODULATING IKB KINASE**

**POWER OF ATTORNEY FOR PATENT APPLICATION**

Mail Stop  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

We, Dr. Elmar-Michael Wein and Dr. Johann Then, Authorized Signatories of Aventis Pharma Deutschland GmbH, Assignee of the above-identified Application, hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as attorneys and/or agents with full power to prosecute this application on behalf of Assignee and to transact all of Assignee's business in connection with the above-identified Application in the Patent and Trademark Office:

Customer No.: **005487**

Effective Date: August 18, 2003

By: ppu *Elmar*  
Dr. Elmar-Micheal Wein  
Title: Prokurst  
Date: 19. NOV. 2003

By: i.v. *Johann*  
Dr. Johann Then  
Title: Authorized Signatory  
Date: \_\_\_\_\_

Address correspondence and telephone calls to:  
Julie Anne Knight, Reg. No. 48,867  
Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-3679  
Telefax (908) 231-2626